title: Assessment of choroidal topographic changes by swept source optical coherence tomography after photodynamic therapy for central serous chorioretinopathy.
abstract: OBJECTIVE
  To investigate the relationship between choroidal thickness and angiographic abnormalities in central serous chorioretinopathy (CSC) eyes by swept-source optical coherence tomography (swept-OCT), before and after half-fluence photodynamic therapy (PDT).
  
  
  METHODS
  Prospective interventional case series.
  
  
  METHODS
  Consecutive patients presenting with treatment-naive active CSC underwent a complete ophthalmologic examination, including swept-OCT at study entry and at 7 days and 30 days after treatment with half-fluence PDT. The main outcome measures were changes in choroidal maps after PDT (mean ± SD) and the relationship between choroidal thickness and angiographic abnormalities.
  
  
  RESULTS
  Of 12 patients (2 females, 10 males; mean age, 55.6 ± 14.0 years), 12 eyes were included. At study entry, mean choroidal thickness measured in the center of the fovea was significantly thicker in the study eyes as compared to the fellow eyes (420.7 ± 107.5 μm vs 349.2 ± 109.7 μm, respectively; P = 0.016). Mean choroidal thickness in the center of the fovea significantly decreased in the study eyes at both 7 days (380.2 ± 113 μm; P = 0.005) and 30 days after PDT (362.3 ± 111 μm; P = 0.002). A similar significant choroidal thinning was recorded in each early treatment of diabetic retinopathy study (ETDRS) applied to 3D swept-OCT maps. At each time point, mean choroidal thickness was significantly thicker in sectors with than in sectors without angiographic abnormalities (421 ± 102.4 μm vs 397.6 ± 96.5 μm, P = 0.002 at study entry; 381.2 ± 106.6 μm vs 364 ± 101.2 μm, P = 0.01 at day 7; 366.3 ± 103.2 μm vs 347.2 ± 99.6 μm at day 30).
  
  
  CONCLUSIONS
  Using swept-OCT, we demonstrated that in active CSC, choroidal thickness is increased to a greater extent in areas characterized by angiographic abnormalities. This increased choroidal thickness may persist even after PDT.
authors.affiliation: Department of Ophthalmology, University of Paris Est Creteil, Centre Hospitalier Intercommunal de Creteil, Creteil, France; Transparence Eye Clinic, Tours, France.
authors.forename: Sam
authors.initials: S
authors.lastname: Razavi
authors.affiliation: Department of Ophthalmology, University of Paris Est Creteil, Centre Hospitalier Intercommunal de Creteil, Creteil, France.
authors.forename: Eric H
authors.initials: EH
authors.lastname: Souied
authors.affiliation: Department of Ophthalmology, University of Paris Est Creteil, Centre Hospitalier Intercommunal de Creteil, Creteil, France.
authors.forename: Edoardo
authors.initials: E
authors.lastname: Cavallero
authors.affiliation: Department of Ophthalmology, Hotel Dieu University Hospital, Nantes, France.
authors.forename: Michel
authors.initials: M
authors.lastname: Weber
authors.affiliation: Department of Ophthalmology, University of Paris Est Creteil, Centre Hospitalier Intercommunal de Creteil, Creteil, France. Electronic address: giuseppe.querques@hotmail.it.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Querques
mesh_terms: D000328:Adult; D000368:Aged; D056833:Central Serous Chorioretinopathy / Q000175:diagnosis* / Q000188:drug therapy*; D002829:Choroid / Q000473:pathology*; D004396:Coloring Agents; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D021621:Imaging, Three-Dimensional; D007208:Indocyanine Green; D008297:Male; D008875:Middle Aged; D009929:Organ Size; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use; D011166:Porphyrins / Q000627:therapeutic use; D011446:Prospective Studies; D041623:Tomography, Optical Coherence; D019371:Topography, Medical; D000077362:Verteporfin
chemical_list: D004396:Coloring Agents; D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin; D007208:Indocyanine Green